Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMO lens solution re-entry

This article was originally published in The Gray Sheet

Executive Summary

Firm will reintroduce a Complete brand of multipurpose lens solution in the United Sates in early August, with wide availability expected by September, AMO says July 23. The company will phase in the product globally throughout the fall. AMO withdrew its Complete MoisturePlus multipurpose solution from the market in May due to links to increased incidence of Acanthamoeba keratitis eye infections among users (1"The Gray Sheet" July 2, 2007, p. 12)...

You may also be interested in...



AMO’s Complete MoisturePlus

Advanced Medical Optics' voluntary recall in May of the multipurpose contact lens solution is classified as Class I by FDA, meaning the product poses a "reasonable probability" of serious adverse health consequences, namely the rare eye infection Acanthamoeba keratitis. The firm is rolling out a replacement Complete multipurpose solution this month (1"The Gray Sheet" July 30, 2007, In Brief)...

AMO Lens Solution Recall Will Cut Sales By Up To $120 Million In 2007

The fallout from Advanced Medical Optics' May recall of its Complete MoisturePlus multipurpose contact lens solution will include lost sales of $100 million to $120 million this year, the firm projects

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

UsernamePublicRestriction

Register

MT025061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel